BioLineRx Ltd. (BLRX)
Oxford Ledge is still expanding full research coverage of BLRX. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
BioLineRx is an Israeli biopharmaceutical company developing oncology and rare disease therapies, including the approved drug APHEXDA and the novel candidate GLIX1.
Source: 20-F (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 6-K Interim report (foreign private issuer) 2026-07-08
- 6-K Interim report (foreign private issuer) 2026-05-27
- 6-K Interim report (foreign private issuer) 2026-05-22
- 6-K Interim report (foreign private issuer) 2026-05-19
- 6-K Interim report (foreign private issuer) 2026-04-28
Source: SEC EDGAR.
Annual results
5 years of annual figures for BLRX, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2024 | $394.9M | $51.6M | $1.20 |
| 2023 | $356.5M | $428,000 | $0.01 |
| 2022 | $309.4M | -$8.0M | -$0.22 |
| 2021 | $259.7M | -$22.6M | -$0.62 |
| 2020 | $167.0M | -$85.4M | -$2.40 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open BLRX in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.